4CPS-267 Lack of hepatitis C virus uptake in HIV/HCV co-infected patients

BackgroundStrategic plans have been developed to eradicate HCV worldwide.Understanding patient factors associated with being untreated for HCV would help in supporting extra efforts in those patients to achieve HCV elimination in the coming years.PurposeWe evaluated the implementation of our country...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A193-A193
Main Authors: Brieva Herrero, MT, Reyes Torres, I, Sáez-Torres de Vicente, M, López López, P, Frias Casas, M, Rivero Juárez, A
Format: Article
Language:English
Subjects:
Hepatitis C
Strategic planning
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundStrategic plans have been developed to eradicate HCV worldwide.Understanding patient factors associated with being untreated for HCV would help in supporting extra efforts in those patients to achieve HCV elimination in the coming years.PurposeWe evaluated the implementation of our country’s strategy in HIV/HCV coinfected patients and barriers to lower treatment implementation in this population.Material and methodsThe HERACLES cohort is a multicentre, prospective observational cohort initiated in April 2015, which includes HIV-infected patients with active chronic HCV coinfection in follow-up at 19 centres for the care of HIV-infected patients from 1 May 2015 to 1 May 2017 (accession number: NCT02511496).The main study outcome was receipt of HCV DAAs treatment from 1 May 2015 to 1 May 2017.Variables identified as factors associated with lower treatment rate implementation were included in a logistic regression model for HCV treatment uptake.ResultsOf the 15,556 HIV patients in care, 3075 (19.7%) presented with active chronic HCV infection and constituted the study population. By the end of the follow-up, 1957 patients initiated HCV therapy (63.6%).In the multivariate analysis, an age lower than 50 years (OR (95% CI)=1,379 (1,109 to 1,713)), absence of or minimal liver fibrosis (F3: OR (95% CI)=9,866 (7,496 to 12,985); F4: OR (95% CI)=14.865 (10,786 to 12,985)), treatment-naïve patients (DAAs+Peg-IFN/RBV: OR: 95% CI=6.493: (3.081 to 10.878)), HCV genotype 3 infection (OR (95% CI)=0.689 (0.523–0.908)), people who injected drugs using opioid substitutive therapy (OST-PWIDs: OR: 95% CI=0.738: (0.588–0.927)), and recent PWIDs were identified as significant independent risk factors associated with low DAA implementation (OR: 95% CI=0.22 (0.005 to 0.092)).ConclusionIn the study period, a high number of HIV/HCV coinfected patients from our cohort received DAA therapy.We identified factors, which did not include prioritisation of DAAs uptake strategy, that limited the access to HCV therapy. The low treatment uptake in several populations seriously jeopardises the completion of the HCV elimination in the coming years.References and/or acknowledgementsNo conflict of interest.
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.416